LncRNA SNHG3 is activated by E2F1 and promotes proliferation and migration of non-small-cell lung cancer cells through activating TGF-β pathway and IL-6/JAK2/STAT3 pathway.


Journal

Journal of cellular physiology
ISSN: 1097-4652
Titre abrégé: J Cell Physiol
Pays: United States
ID NLM: 0050222

Informations de publication

Date de publication:
03 2020
Historique:
received: 07 05 2019
accepted: 03 09 2019
pubmed: 12 10 2019
medline: 17 12 2020
entrez: 12 10 2019
Statut: ppublish

Résumé

Recently, long noncoding RNAs (lncRNAs) have been widely reported to play pivotal roles in the regulation of human cancers. Although the oncogenic property of lncRNA small nucleolar RNA host gene 3 (SNHG3) has been revealed in a variety of cancers, functions and regulatory mechanism of SNHG3 in non-small-cell lung cancer (NSCLC) remain to be investigated. In this study, we detected the upregulated expression of SNHG3 in NSCLC tissues as well as cells through quantitative reverse-transcription polymerase chain reaction (qRT-PCR) analysis. Using Kaplan-Meier analysis, we determined that a high-level of SNHG3 was associated with a low overall survival rate of patients with NSCLC. Through gain and loss of function experiments, we demonstrated that SNHG3 had a significantly positive effect on NSCLC cell proliferation and migration. Mechanistic investigations revealed that SNHG3 was a predicted direct transcriptional target of E2F1. We observed that the transcriptional activation of SNHG3 could be induced by E2F1. To explore the mechanism, rescue experiments were carried out, which revealed that the cotreatment with SB-431542, JSI-124, or JSI-124 + SB-431542 rescued the effects brought by the overexpression of SNHG3 on NSCLC cell proliferation, migration, and epithelial-mesenchymal transition process. Our results suggested that E2F1 activated SNHG3 and promoted cell proliferation and migration in NSCLC via transforming growth factor-β pathway and interleukin-6/janus-activated kinase 2/signal transducer and activator of transcription 3 pathway, which implied that SNHG3 may be a biomarker for the treatment of patients with NSCLC.

Identifiants

pubmed: 31602642
doi: 10.1002/jcp.29194
doi:

Substances chimiques

E2F1 Transcription Factor 0
E2F1 protein, human 0
E2f1 protein, mouse 0
Interleukin-6 0
RNA, Long Noncoding 0
STAT3 Transcription Factor 0
Transforming Growth Factor beta 0
Janus Kinase 2 EC 2.7.10.2

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2891-2900

Informations de copyright

© 2019 Wiley Periodicals, Inc.

Auteurs

Jindong Shi (J)

Department of Respiratory Medicine, The Fifth People's Hospital of Shanghai, Fudan University, Shanghai, China.

Jiannan Li (J)

Department of Respiratory Medicine, The Fifth People's Hospital of Shanghai, Fudan University, Shanghai, China.

Shuang Yang (S)

General Department, Jiangchuan Community Healthcare Service Center, Shanghai, China.

Xiaoying Hu (X)

General Department, Jiangchuan Community Healthcare Service Center, Shanghai, China.

Jiajun Chen (J)

Department of Respiratory Medicine, The Fifth People's Hospital of Shanghai, Fudan University, Shanghai, China.

Jingjing Feng (J)

Department of Respiratory Medicine, The Fifth People's Hospital of Shanghai, Fudan University, Shanghai, China.

Tianyun Shi (T)

Department of Respiratory Medicine, The Fifth People's Hospital of Shanghai, Fudan University, Shanghai, China.

Yanchao He (Y)

Department of Respiratory Medicine, The Fifth People's Hospital of Shanghai, Fudan University, Shanghai, China.

Zhoufang Mei (Z)

Department of Respiratory Medicine, The Fifth People's Hospital of Shanghai, Fudan University, Shanghai, China.

Wei He (W)

Department of Respiratory Medicine, The Fifth People's Hospital of Shanghai, Fudan University, Shanghai, China.

Juan Xie (J)

Department of Respiratory Medicine, The Fifth People's Hospital of Shanghai, Fudan University, Shanghai, China.

Shanqun Li (S)

Department of Respiratory Medicine, Zhongshan Hospital, Fudan University, Shanghai, China.

Zhijun Jie (Z)

Department of Respiratory Medicine, The Fifth People's Hospital of Shanghai, Fudan University, Shanghai, China.

Shuiping Tu (S)

Department of Oncology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH